Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis.
Min Qin, Guobing Yang, Jun Yan, Liying Wang, Yu Feng, Dong Wang, Qian Wang, Yanyan Hou, Jiangshan Zhao, Jiaxi Lei, Zhiyi Wang, Mingzhe Jiang, Chenghang Yu, Laurent Gavotte, Roger Frutos
Author Information
Min Qin: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Guobing Yang: Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China.
Jun Yan: Chinese Centre for Disease Control and Prevention, Beijing, China. yanjun@chinacdc.cn.
Liying Wang: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China. wangliyingcdc@163.com. ORCID
Yu Feng: Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China.
Dong Wang: Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China.
Qian Wang: Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China.
Yanyan Hou: Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, China.
Jiangshan Zhao: Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, China.
Jiaxi Lei: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Zhiyi Wang: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Mingzhe Jiang: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Chenghang Yu: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Laurent Gavotte: Espace-Dev, UMR 228, Université de Montpellier, Montpellier, France.
Roger Frutos: Centre de Cooperation International en Recherche Agronomique Pour Le Développement, UMR 17, Intertryp, Campus International de Baillarguet, Montpellier, France.
BACKGROUND: Echinococcosis is an infectious parasitic disease that is extremely harmful to human health. Albendazole is provided free of charge to patients requiring medication under the central government finance transfer payment scheme for Echinococcosis control and prevention in China. Our aim is to monitor the state of patient medication and its therapeutic impact, which will help improve medication compliance and the therapeutic effect. METHODS: Random cluster sampling was used to select 10 Echinococcosis-endemic counties in China, and all Albendazole-treated patients in these counties were investigated. The chi-square and Kruskal-Wallis tests were used to compare two or more rates or constituent ratios, and multiple logistic regression analysis was used to identify the influencing factors. The records of patients were reviewed to obtain the initial diagnosis results as well as the most recent follow-up results and time, and efficacy was assessed. RESULTS: We examined 899 patient files treated with Albendazole in 10 endemic counties. Of the 582 evaluable files, 7.9% did not take Albendazole, and 69.2% did not take Albendazole regularly. Only 22.9% took Albendazole regularly. Of the 536 patients who took Albendazole, 242 exhibited adverse reactions. patients who were Tibetan, herdsmen, received no formal education, used emulsion, and exhibited adverse reactions demonstrated poor compliance. A total of 174 patients with cystic Echinococcosis received their most recent imaging follow-up results within one year of the investigation date. Among them, 9 patients met the criteria for cure, accounting for 5.2%; 56 patients showed effectiveness, accounting for 32.2%; 105 patients were deemed ineffective, accounting for 59.8%; 5 patients experienced recurrence, accounting for 2.9%. CONCLUSIONS: Albendazole medication compliance in patients with Echinococcosis is not ideal. We must prioritize health education and promotion for Tibetans, herdsmen, and those without formal education. patients who adhered to their medication regimen achieved higher rates of cure and effectiveness. To improve medication compliance and efficacy, it is particularly important to improve communication and medication guidance for patients receiving emulsions and those with adverse reactions after taking Albendazole. Simultaneously strengthen patients' attention to follow-up and re-examination.
